Crystal Research Associates has released a new Executive Informational Overview (EIO) on XBiotech Inc. (XBIT-NASDAQ), a company engaged in discovering, developing, and translating natural human immunity into novel therapeutic antibody products. The 60-page EIO, which details XBiotech's business, technology and product development, manufacturing expertise, market opportunities, competition, and more, is available for download below.

Specialty biopharmaceutical company Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX) announced this morning that it has entered into a promotional services agreement with EMD Serono, Inc., the U.S. and Canadian biopharmaceutical businesses of Merck KGaA (MRK-NYSE). Under the agreement, Aeterna can begin promoting Saizen® [somatropin (rDNA origin) for injection] to designated medical professionals in specified territories in the U.S. Aeterna will work within the realm of field promotion of Saizen® by driving awareness of the product among medical professionals, and expects to be compensated on the basis of new, eligible patient starts on Saizen® above an agreed-upon baseline. This is the second promotional services agreement for Aeterna in recent months, as the company accelerates its transition into a commercially operating specialty biopharma by leveraging its sales force.

• Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF

• Patent Issuance Will Provide Additional IP Protection for MANF Protein Therapy and Cell Therapy

SAN FRANCISCO and GENEVA, May 5, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/305,025 entitled, "Dopaminergic Neuronal Survival Promoting Factors and Uses Thereof." Upon issuance, the patent will provide additional intellectual property protection for MANF (mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell therapy. The allowed patent claims cover compositions of matter and methods of use related to the Company's proprietary manufacturing process for synthetic MANF and its administration.